A study that connects Ozempic to treat obesity and injuries with a rare type of blindness

A new research has shown a link between taking a means of treating obesity and infection with a rare type of blindness, and the study published in the Journal of the American Medical Association said that patients who used the “simaglotide”, which are commercially sold in the name Ozempic, to develop anxiety, the most common form of optical neurological anxiety. Among adults. Last summer, doctors at Massachusetts Hospital noticed a number of patients with “arterial anterior anterior mythical neuropathy”, and this disease causes sudden and painless vision loss in one eye, due to a weak blood flow to the front of the optic nerve, and is often associated with lack of small blood vessels. The disease usually affects individuals older than 50 years old, and is related to various risk factors such as high blood pressure, diabetes, sleep breathing, atherosclerosis, and this condition is the result of insufficient perfusion in the head of the optic nerve, resulting in damage to nerve fibers and later vision. A lack of perfusion is defined as an inadequate blood supply of specific tissues in the body to block the nourishing blood vessels. Although microscopic physiology is still unclear, it involves an imbalance in regulating blood vessels and possibly low blood pressure, and these patients are clinically diagnosed, and although there is no final treatment, the management of basic risk factors is very important, to prevent more attacks and maintain vision, and because this disease is relatively rare; Doctors have decided to follow these matters to find out why they have this rare condition. Nerve -eye medicine analyzed data of 16.827 patients referred to nervous vocational evaluations between December 1, 2017 and November 30, 2023, and with the exception of individuals under the age of 12, the qualified group consisted of 710 patients with type 2 diabetes, and 979 patients who were 59 years, 52% of the age of the type 2 Year, 59 years of females, while the average age of the group was extra weight or obesity 47 years, with 72% of women. Of the 710 patients suffering from Type 2 diabetes, 17 patients were sick with blindness caused by that disease within the ‘Simaglotide’ group, compared to 6 in the group that did not contain the drug, and the average age was 57 years for the ‘simaglotide’ group, and 58 years of the group who did not take the drug, and over the course of 36 months was injured by 8.9% over the course of 36 months. “. 1.8% for the group you do not eat. The group suffering from weight gain or obesity included 979 patients. The infection of the anterior anterior mythical neurological analogy was observed in 20 patients in the ‘Simaglotide’ group, compared to 3 in the group that did not take the drug, and the average age was 46 years for the ‘Simajlotide’ which does not take the cure. The study found that patients who took the medicine “simaglotide” are four times more likely to develop blindness compared to patients who do not get that medicine, while the study highlights a possible relationship between the use of ‘simaglotide’ and the increased risk of this rare type of blindness. What is ozmpic? “Simaglotide” is a drug used primarily to treat type 2 diabetes and obesity, and it belongs to a group of drugs known as the “peptide-1” bachelors that similar to glucagon (GLP-1), and simulates the work of that hormone, which plays Several Majorism and Regulation of Appetite, and is sold under multiple commercial names, the most famous of which is ozempic. The stimuli of the Better-1 receptors were approved in 2005 to treat type 2 diabetes, and to manage weight in 2014, and the interest in this medicine was partially driven by voting to simjlotide in 2021 to manage weight. According to a previous report; About three -quarters of the Americans say they heard about the medicine, and other similar medicines used to lose weight, and among those familiar with this medicine, 53% believe it is good options for weight loss for obese people, or a healthy condition related to weight, while only 19% believe it is not good options, 28% say they are not sure. In a study published weeks ago, it was said that nearly 31,000 children are between 12 and 17 years old and that more than 162,000 people between the ages of 18 and 25 used this medicine in 2023 alone. The demand for that medicine led to a lack of supply, which expressed concern about the use of the poster, and the effects on people who depend on this medicine to manage their health conditions; The World Health Organization also issued a warning about the existence of false packages of that medicine. “Simaglotide” stimulates the pancreas to produce more insulin in response to high blood sugar levels, which helps reduce blood sugar levels by increasing glucose absorption by increasing tissues; It also prevents the secretion of glucagon, which is the hormone that increases the levels of glucose in the blood by stimulating the liver, to release the stored glucose. By obstructing the release of glucagon, “simaglotide” helps reduce the amount of glucose launched in the bloodstream, and the remedy slows down the emptying of the stomach, which helps reduce the rate of glucose access to the bloodstream after eating the bloodstream. The remedy works on the brain, to reduce appetite, increase saturation, which eats and thus reduces weight loss, which is especially useful for patients suffering from obesity or weight gain. It has been shown that the GLP-1 receptors, including ‘Simaglotide’, have favorable effects on heart health and blood vessels, including reducing the risk of large cardiovascular events in patients with type 2 diabetes. But there are many hypotheses that can explain this potential link. Simajlotide, like all other GLP-1 receptors, can affect the blood flow and the blood vessel function, and it is believed that the infection is that the disease occurs due to insufficient blood flow to the optic nerve, which can be exacerbated by the middle of the drug. Previous studies have also indicated that GLP-1 receptors affect blood pressure, and that the fluctuations in blood pressure, especially night blood pressure, risk factors for that disease, and ‘simaglotide’ can contribute to such fluctuations, which can increase the risk of optical nerve damage. The possibility exists that ‘simaglotide’ will lead to inflammatory reactions that can affect the optic nerve, and inflammation can lead to swelling and pressure of the optic nerve, and patients with type 2 diabetes are often in diabetes, and obesity is pre -existing factors to vascular diseases, including those that affect the eyes and the drug can raise the basic conditions. The study restrictions on the effects of Ozempic There are many limitations that can limit the results of the study. The institution in which the study was conducted, specialized in ophthalmology and neurological ophthalmology, as the results it achieved may not apply to other environments. Since he was retroactively a study, he could not control the potential prejudices in which the medicine was described “simaglotide” to patients, or referred it to the clinic. Researchers also could not verify whether all patients are taking the prescribed medication, which may affect their risk estimates, and the researchers also say that their ability to assess confusing factors is limited; Due to the small number of cases, resulting in less accurate statistics. In addition, researchers could not investigate data from other institutions, and therefore they could not prove the causal relationship.